Ulcerative Colitis

Plevy, will describe results suggesting that oral administration of Guanilib ameliorates inflammation in a mouse model of experimental colitis, presumably via downregulation of the key cytokines, such as tumor necrosis factor, that are known to be involved in the causes of IBD.

For more information on the conference, visit http://www.ddw.org.

Dr.

Scott Plevy, Associate Professor of Medicine and Immunology and the Co-Director of the Inflammatory Bowel Disease Center at the University of Pittsburg Medical Center, Pittsburg, PA is a principle collaborator on Callisto's Guanilib research program.

"We are very encouraged by the Guanilib data from Dr.

Plevy's laboratory, and pleased to have this new research presented to leading research professionals in the field," said Callisto CEO Dr.

Gary S.

Jacob.

"Dr.

Plevy and his group were the first to demonstrate that Guanilib inhibits gastrointestinal inflammation in an animal model of colitis, and now are providing insight into just how Guanilib exerts its antiinflammatory activity.

Their research supports our commitment to pursue development of Guanilib as a completely new approach to the treatment of gastrointestinal disease." One of the major physiological funct...

Read more...